The PARP inhibitor combination cut the risk of radiographic progression by about half in TALAPRO-3. Survival data are still immature, and severe anemia was common.
What Happened
On October 26, 2026, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer) with enzalutamide (Xtandi) for adults with metastatic prostate cancer that has not yet become resistant to hormone therapy and carries a homologous recombination repair (HRR) gene mutation [1]. The label calls this disease "metastatic androgen pathway modulation-naive or -sensitive prostate cancer." Pfizer notes it is also called metastatic hormone-sensitive prostate cancer, the name most clinicians know [2]. Few diseases get renamed into something longer.
Patients must have one of 12 HRR gene alterations, including BRCA1, BRCA2, ATM and PALB2, found by an FDA-authorized test [1]. The approved tests are FoundationOne CDx and FoundationOne Liquid CDx [1]. The FDA granted priority review and ran the review under Project Orbis with Australia's and Canada's regulators [1].
Background
Talazoparib is a PARP inhibitor, a drug that targets cancer cells with defects in DNA repair. Enzalutamide blocks androgen signaling. The FDA first approved the combination in June 2023 for HRR-mutated metastatic castration-resistant prostate cancer, the later, hormone-resistant stage, based on the TALAPRO-2 trial of 399 patients [6]. The new approval moves the combination earlier, to men whose cancer still responds to hormone therapy.
What the Trial Found
The approval rests on TALAPRO-3 (NCT04821622), a randomized, double-blind, placebo-controlled trial of 599 patients [1]. Patients received enzalutamide plus either talazoparib or placebo, and all continued androgen deprivation therapy [1]. The primary endpoint was radiographic progression-free survival (rPFS), assessed by investigators [1].
Median rPFS was not reached with talazoparib, versus 45.8 months with placebo (hazard ratio 0.48; 95% CI, 0.36-0.65; p<0.0001) [1]. Pfizer reported that about 77% of patients on the combination were progression-free at three years, compared with 56% on enzalutamide alone [3]. The benefit appeared in both BRCA-mutated and non-BRCA subgroups, though it was larger in BRCA-mutated patients (HR 0.37 vs 0.57) [3].
An overall survival benefit has not been shown. The FDA states that survival data were immature at the time of the analysis [1]. In the interim analysis presented at ASCO, the survival hazard ratio was 0.77 (95% CI, 0.56-1.04; p=0.09), which was not statistically significant [3].
Safety and Limitations
The main trade-off is blood toxicity. Grade 3 or higher anemia occurred in 51% of patients on talazoparib, compared with 3% on placebo, and 5% stopped talazoparib because of anemia [3][8]. Transfusions were given to 40% of patients on the combination versus 2% on placebo [5]. Grade 3 or 4 adverse events occurred in 79% versus 41% of patients [4]. Two deaths in the talazoparib group were judged treatment-related, one from pancytopenia and one from idiopathic pulmonary fibrosis [4]. The FDA label warns of myelodysplastic syndrome and acute myeloid leukemia, myelosuppression and harm to a fetus [1].
Pfizer funded TALAPRO-3 [5]. The results were presented at the 2026 ASCO Annual Meeting and, according to Pfizer, published in The New England Journal of Medicine [3]. Because overall survival is not yet mature, it is not known whether the earlier rPFS benefit will translate into longer life.
What Comes Next
The FDA lists overall survival as an additional endpoint still being followed [1]. A European application is under review [2]. Analysts at RBC Capital Markets called the approval a "win for patients" but expected a negligible financial impact for Pfizer, according to Fierce Pharma [7]. For patients, the practical message from the approval is that HRR genetic testing now matters at an earlier stage of metastatic prostate cancer.
This article is for informational purposes only. Readers should consult their clinician about any health concerns.
References
U.S. Food and Drug Administration. "FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naive or -sensitive prostate cancer." October 26, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive
Pfizer. "Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting." Business Wire, via BioSpace. October 26, 2026. https://www.biospace.com/press-releases/pfizers-talzenna-plus-xtandi-fda-approved-for-an-earlier-metastatic-prostate-cancer-treatment-setting
Pfizer. "TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer." Business Wire. May 30, 2026. NEJM DOI as reported: 10.1056/NEJMoa2604126. https://www.businesswire.com/news/home/20260530351488/en/
Broderick JM. "Talazoparib Plus Enzalutamide Cuts Progression Risk by 52% in HRR-Altered mCSPC." Targeted Oncology. May 31, 2026. https://www.targetedonc.com/view/talazoparib-plus-enzalutamide-cuts-progression-risk-by-52-in-hrr-altered-mcspc
Barbor M. "HRR-Altered Metastatic Prostate Cancer: Talazoparib Plus Enzalutamide Improves Progression-Free Survival." The ASCO Post. August 6, 2026. https://ascopost.com/news/august-2026/hrr-altered-metastatic-prostate-cancer-talazoparib-plus-enzalutamide-improves-progression-free-survival/
U.S. Food and Drug Administration. "FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer." June 20, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate
Coffey D. "Pfizer's Talzenna climbs treatment line with new FDA okay in prostate cancer." Fierce Pharma. October 26, 2026. https://www.fiercepharma.com/pharma/pfizers-talzenna-climbs-treatment-line-new-fda-okay-prostate-cancer
Kariyawasam-Chavez R. "FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer." Pharmacy Times. October 26, 2026. https://www.pharmacytimes.com/view/fda-approves-talazoparib-with-enzalutamide-for-hrr-mutated-metastatic-prostate-cancer
